{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:45:30Z","timestamp":1761061530704,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004366","name":"tabriz university of medical sciences","doi-asserted-by":"crossref","award":["57664"],"award-info":[{"award-number":["57664"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11033-021-06778-z","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T20:47:22Z","timestamp":1637786842000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-0815","authenticated-orcid":false,"given":"Raedeh","family":"Saraei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heshu Sulaiman","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-9749","authenticated-orcid":false,"given":"Mohammad","family":"Asghari-Jafarabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-6845","authenticated-orcid":false,"given":"Adel","family":"Naimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-1145","authenticated-orcid":false,"given":"Ali","family":"Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-3551","authenticated-orcid":false,"given":"Saeed","family":"Solali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"53","key":"6778_CR1","first-page":"355","volume":"10","author":"J Arrondeau","year":"2010","unstructured":"Arrondeau J, Gan HK, Razak AR, Paoletti X, Le Tourneau C (2010) Development of anti-cancer drugs. Discov Med 10(53):355\u2013362","journal-title":"Discov Med"},{"key":"6778_CR2","volume-title":"Cancer facts & figures 2015","author":"R Siegel","year":"2015","unstructured":"Siegel R, Jemal A (2015) Cancer facts & figures 2015. American Cancer Society, Atlanta"},{"issue":"4","key":"6778_CR3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","volume":"30","author":"J Kiladjian","year":"2016","unstructured":"Kiladjian J, Giraudier S, Cassinat B (2016) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30(4):776\u2013781","journal-title":"Leukemia"},{"issue":"3","key":"6778_CR4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40291-018-0329-9","volume":"22","author":"AP Mishra","year":"2018","unstructured":"Mishra AP, Salehi B, Sharifi-Rad M, Pezzani R, Kobarfard F, Sharifi-Rad J et al (2018) Programmed cell death, from a cancer perspective: an overview. Mol Diagn Ther 22(3):281\u2013295","journal-title":"Mol Diagn Ther"},{"issue":"3","key":"6778_CR5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.4049\/jimmunol.168.3.1356","volume":"168","author":"E Cretney","year":"2002","unstructured":"Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168(3):1356\u20131361","journal-title":"J Immunol"},{"issue":"21","key":"6778_CR6","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","volume":"26","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A, Holland P, Eckhardt SG (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL). J Clin Oncol 26(21):3621\u20133630","journal-title":"J Clin Oncol"},{"key":"6778_CR7","volume-title":"TRAIL of hope meeting resistance in cancer","author":"D Deng","year":"2020","unstructured":"Deng D, Shah K (2020) TRAIL of hope meeting resistance in cancer. Elsevier, Amsterdam"},{"key":"6778_CR8","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.biopha.2018.08.065","volume":"107","author":"R Saraei","year":"2018","unstructured":"Saraei R, Soleimani M, Akbari AAM, Hagh MF, Hassanzadeh A, Solali S (2018) The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Biomed Pharmacother 107:1010\u20131019","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"6778_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3892\/ijo.2016.3525","volume":"49","author":"Y Huang","year":"2016","unstructured":"Huang Y, Yang X, Xu T, Kong Q, Zhang Y, Shen Y et al (2016) Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs. Int J Oncol 49(1):153\u2013163","journal-title":"Int J Oncol"},{"issue":"1","key":"6778_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-016-0140-0","volume":"35","author":"Y Leng","year":"2016","unstructured":"Leng Y, Qiu L, Hou J, Zhao Y, Zhang X, Yang S et al (2016) Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Chin J Cancer 35(1):1\u20137","journal-title":"Chin J Cancer"},{"key":"6778_CR11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2020.07.013","volume":"326","author":"B Thapa","year":"2020","unstructured":"Thapa B, Remant K, Uluda\u011f H (2020) TRAIL therapy and prospective developments for cancer treatment. J Control Release 326:335\u2013349","journal-title":"J Control Release"},{"issue":"18","key":"6778_CR12","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s00018-010-0407-6","volume":"67","author":"G Jacquemin","year":"2010","unstructured":"Jacquemin G, Shirley S, Micheau O (2010) Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell Mol Life Sci 67(18):3115\u20133130","journal-title":"Cell Mol Life Sci"},{"issue":"18","key":"6778_CR13","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.3390\/molecules25184073","volume":"25","author":"W Alam","year":"2020","unstructured":"Alam W, Khan H, Shah MA, Cauli O, Saso L (2020) Kaempferol as a dietary anti-inflammatory agent: current therapeutic standing. Molecules 25(18):4073","journal-title":"Molecules"},{"issue":"4","key":"6778_CR14","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.foodchem.2012.11.139","volume":"138","author":"AY Chen","year":"2013","unstructured":"Chen AY, Chen YC (2013) A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem 138(4):2099\u20132107","journal-title":"Food Chem"},{"issue":"3\/4","key":"6778_CR15","first-page":"379","volume":"6","author":"AY Chen","year":"2013","unstructured":"Chen AY, Chen YC (2013) Multipotent Flavonoid Kaempferol: Molecular Targets and Mechanism of Action and Nanotechnology Applications in Cancer and Human Health. Chemical Physics Research Journal 6(3\/4):379","journal-title":"Chemical Physics Research Journal"},{"issue":"4","key":"6778_CR16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/jcb.22044","volume":"106","author":"G Marfe","year":"2009","unstructured":"Marfe G, Tafani M, Indelicato M, Sinibaldi-Salimei P, Reali V, Pucci B et al (2009) Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem 106(4):643\u2013650","journal-title":"J Cell Biochem"},{"key":"6778_CR17","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.12659\/MSM.903552","volume":"23","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Tian B, Wang Y, Ding H (2017) Kaempferol sensitizes human ovarian cancer cells-ovcar-3 and skov-3 to tumor necrosis factor-related apoptosis-inducing ligand (trail)-induced apoptosis via jnk\/erk-chop pathway and up-regulation of death receptors 4 and 5. Med Sci Monit 23:5096","journal-title":"Med Sci Monit"},{"key":"6778_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/731940","author":"E Szliszka","year":"2013","unstructured":"Szliszka E, Krol W (2013) Polyphenols isolated from propolis augment TRAIL-induced apoptosis in cancer cells. Evid-Based Complem Altern Med. https:\/\/doi.org\/10.1155\/2013\/731940","journal-title":"Evid-Based Complem Altern Med"},{"key":"6778_CR19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jim.2015.04.025","volume":"423","author":"S Pietkiewicz","year":"2015","unstructured":"Pietkiewicz S, Schmidt JH, Lavrik IN (2015) Quantification of apoptosis and necroptosis at the single cell level by a combination of imaging flow cytometry with classical annexin V\/propidium iodide staining. J Immunol Methods 423:99\u2013103","journal-title":"J Immunol Methods"},{"issue":"2","key":"6778_CR20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4149\/neo_2013_030","volume":"60","author":"S Leahomschi","year":"2013","unstructured":"Leahomschi S, Molinsky J, Klanova M, Andera L, Peterka M, Gasova Z et al (2013) Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL). Neoplasma 60(2):223\u2013231","journal-title":"Neoplasma"},{"issue":"1","key":"6778_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/1535-7163.MCT-13-0153","volume":"13","author":"D Finlay","year":"2014","unstructured":"Finlay D, Vamos M, Gonz\u00e1lez-L\u00f3pez M, Ardecky RJ, Ganji SR, Yuan H et al (2014) Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther 13(1):5\u201315","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"6778_CR22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7150\/ijbs.30847","volume":"15","author":"Y Deng","year":"2019","unstructured":"Deng Y, Bi R, Guo H, Yang J, Du Y, Wang C et al (2019) Andrographolide enhances TRAIL-induced apoptosis via p53-mediated death receptors up-regulation and suppression of the NF-\u043aB pathway in bladder cancer cells. Int J Biol Sci 15(3):688","journal-title":"Int J Biol Sci"},{"issue":"5","key":"6778_CR23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/cdd.2017.40","volume":"24","author":"A Haimovici","year":"2017","unstructured":"Haimovici A, Humbert M, Federzoni EA, Shan-Krauer D, Brunner T, Frese S et al (2017) PU. 1 supports TRAIL-induced cell death by inhibiting NF-\u03ba B-mediated cell survival and inducing DR5 expression. Cell Death Differ 24(5):866\u2013877","journal-title":"Cell Death Differ"},{"key":"6778_CR24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jbior.2017.10.006","volume":"67","author":"BC Leonard","year":"2018","unstructured":"Leonard BC, Johnson DE (2018) Signaling by cell surface death receptors: alterations in head and neck cancer. Adv Biol Regul 67:170\u2013178","journal-title":"Adv Biol Regul"},{"issue":"6","key":"6778_CR25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","volume":"19","author":"M Holtz","year":"2005","unstructured":"Holtz M, Forman S, Bhatia R (2005) Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19(6):1034","journal-title":"Leukemia"},{"issue":"21","key":"6778_CR26","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/blood.V116.21.4465.4465","volume":"116","author":"D Devlin","year":"2010","unstructured":"Devlin D, Szegezdi E, Tanja P, Orosz O, O\u2019Dwyer M, Carty M et al (2010) G2\/M arrest sensitizes chronic myelogenous leukemia cells to TRAIL-induced apoptosis. Blood 116(21):4465","journal-title":"Blood"},{"issue":"32","key":"6778_CR27","doi-asserted-by":"crossref","first-page":"11317","DOI":"10.1073\/pnas.0801868105","volume":"105","author":"AJ Frew","year":"2008","unstructured":"Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA et al (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci 105(32):11317\u201311322","journal-title":"Proc Natl Acad Sci"},{"issue":"33","key":"6778_CR28","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1016\/j.biomaterials.2011.07.051","volume":"32","author":"HH Jiang","year":"2011","unstructured":"Jiang HH, Kim TH, Lee S, Chen X, Youn YS, Lee KC (2011) PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 32(33):8529\u20138537","journal-title":"Biomaterials"},{"issue":"1","key":"6778_CR29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2008.07.131","volume":"375","author":"T Yoshida","year":"2008","unstructured":"Yoshida T, Konishi M, Horinaka M, Yasuda T, Goda AE, Taniguchi H et al (2008) Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun 375(1):129\u2013133","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"6778_CR30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/cr.2009.57","volume":"19","author":"W Tang","year":"2009","unstructured":"Tang W, Wang W, Zhang Y, Liu S, Liu Y, Zheng D (2009) TRAIL receptor mediates inflammatory cytokine release in an NF-\u03baB-dependent manner. Cell Res 19(6):758\u2013767","journal-title":"Cell Res"},{"issue":"26","key":"6778_CR31","doi-asserted-by":"crossref","first-page":"E3355","DOI":"10.1073\/pnas.1504630112","volume":"112","author":"Y-J Jeon","year":"2015","unstructured":"Jeon Y-J, Middleton J, Kim T, Lagan\u00e0 A, Piovan C, Secchiero P et al (2015) A set of NF-\u03baB\u2013regulated microRNAs induces acquired TRAIL resistance in Lung cancer. Proc Natl Acad Sci 112(26):E3355\u2013E3364","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"6778_CR32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1158\/1541-7786.MCR-05-0231","volume":"4","author":"SJ Braeuer","year":"2006","unstructured":"Braeuer SJ, B\u00fcneker C, Mohr A, Zwacka RM (2006) Constitutively activated nuclear factor-\u03baB, but not induced NF-\u03baB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 4(10):715\u2013728","journal-title":"Mol Cancer Res"},{"issue":"6","key":"6778_CR33","first-page":"1498","volume":"36","author":"YS Kim","year":"2002","unstructured":"Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA (2002) TRAIL-mediated apoptosis requires NF-kB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36(6):1498\u20131508","journal-title":"Hepatology"},{"issue":"3","key":"6778_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-2399-y","volume":"11","author":"D Verzella","year":"2020","unstructured":"Verzella D, Pescatore A, Capece D, Vecchiotti D, Ursini MV, Franzoso G et al (2020) Life, death, and autophagy in cancer: NF-\u03baB turns up everywhere. Cell Death Dis 11(3):1\u201314","journal-title":"Cell Death Dis"},{"issue":"1","key":"6778_CR35","doi-asserted-by":"crossref","first-page":"e0171157","DOI":"10.1371\/journal.pone.0171157","volume":"12","author":"PC Liu","year":"2017","unstructured":"Liu PC, Lu G, Deng Y, Wang CD, Su XW, Zhou JY et al (2017) Inhibition of NF-\u03baB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) combination therapy. PLoS ONE 12(1):e0171157","journal-title":"PLoS ONE"},{"issue":"12","key":"6778_CR36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.4103\/jcrt.JCRT_348_18","volume":"14","author":"B Iqbal","year":"2018","unstructured":"Iqbal B, Ghildiyal A, Singh S, Siddiqui S, Kumari P, Arshad M et al (2018) Combinatorial effect of curcumin and tumor necrosis factor-\u03b1-related apoptosis-inducing ligand (TRAIL) in induction of apoptosis via inhibition of nuclear factor kappa activity and enhancement of caspase-3 activity in chronic myeloid cells: an in-vitro study. J Cancer Res Ther 14(12):1193","journal-title":"J Cancer Res Ther"},{"issue":"10","key":"6778_CR37","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.molimm.2006.12.015","volume":"44","author":"JC Morales","year":"2007","unstructured":"Morales JC, Ruiz-Maga\u00f1a MJ, Ruiz-Ruiz C (2007) Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-\u03baB inhibition. Mol Immunol 44(10):2587\u20132597","journal-title":"Mol Immunol"},{"issue":"11","key":"6778_CR38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/onc.2012.164","volume":"32","author":"LY Dimberg","year":"2013","unstructured":"Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32(11):1341","journal-title":"Oncogene"},{"issue":"22","key":"6778_CR39","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1038\/sj.onc.1210985","volume":"27","author":"P Geserick","year":"2008","unstructured":"Geserick P, Drewniok C, Hupe M, Haas T, Diessenbacher P, Sprick M et al (2008) Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL-and CD95L-mediated apoptosis. Oncogene 27(22):3211","journal-title":"Oncogene"},{"issue":"1","key":"6778_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"CHA Cheung","year":"2020","unstructured":"Cheung CHA, Chang Y-C, Lin T-Y, Cheng SM, Leung E (2020) Anti-apoptotic proteins in the autophagic world: an update on functions of XIAP, Survivin, and BRUCE. J Biomed Sci 27(1):1\u201310","journal-title":"J Biomed Sci"},{"issue":"1","key":"6778_CR41","first-page":"1","volume":"11","author":"GE Naoum","year":"2017","unstructured":"Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO (2017) Journey of TRAIL from bench to bedside and its potential role in immuno-oncology. Oncol Rev 11(1):1","journal-title":"Oncol Rev"},{"issue":"4","key":"6778_CR42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bcp.2014.08.010","volume":"91","author":"IA van Roosmalen","year":"2014","unstructured":"van Roosmalen IA, Quax WJ, Kruyt FA (2014) Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function? Biochem Pharmacol 91(4):447\u2013456","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"6778_CR43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/157489211796957739","volume":"6","author":"J Gerspach","year":"2011","unstructured":"Gerspach J, Pfizenmaier K, Wajant H (2011) Therapeutic targeting of CD95 and the TRAIL death receptors. Recent Pat Anti-Cancer Drug Discov 6(3):294\u2013310","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"issue":"5","key":"6778_CR44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10495-016-1223-8","volume":"21","author":"MH Raj","year":"2016","unstructured":"Raj MH, Yashaswini B, R\u00f6ssler J, Salimath BP (2016) Combinatorial treatment with anacardic acid followed by TRAIL augments induction of apoptosis in TRAIL resistant cancer cells by the regulation of p53, MAPK and NF\u03ba\u03b2 pathways. Apoptosis 21(5):578\u2013593","journal-title":"Apoptosis"},{"issue":"12","key":"6778_CR45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/0145-2126(93)90161-D","volume":"17","author":"JC Law","year":"1993","unstructured":"Law JC, Ritke MK, Yalowich JC, Leder GH, Ferrell RE (1993) Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 17(12):1045\u20131050","journal-title":"Leuk Res"},{"issue":"23","key":"6778_CR46","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1073\/pnas.93.23.13137","volume":"93","author":"T Skorski","year":"1996","unstructured":"Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Martinez R, Wasik MA et al (1996) Blastic transformation of p53-deficient bone marrow cells by p210bcr\/abl tyrosine kinase. Proc Natl Acad Sci 93(23):13137\u201313142","journal-title":"Proc Natl Acad Sci"},{"issue":"46","key":"6778_CR47","doi-asserted-by":"crossref","first-page":"35418","DOI":"10.1074\/jbc.M110.172767","volume":"285","author":"B Sung","year":"2010","unstructured":"Sung B, Ravindran J, Prasad S, Pandey MK, Aggarwal BB (2010) Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285(46):35418\u201335427","journal-title":"J Biol Chem"},{"issue":"1","key":"6778_CR48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/BJ20082131","volume":"420","author":"S-J Park","year":"2009","unstructured":"Park S-J, Kim M-J, Kim H-B, Kang C-D, Kim S-H (2009) Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Biochem J 420(1):73\u201381","journal-title":"Biochem J"},{"issue":"11","key":"6778_CR49","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1535-7163.MCT-08-0236","volume":"7","author":"MD Siegelin","year":"2008","unstructured":"Siegelin MD, Reuss DE, Habel A, Herold-Mende C, von Deimling A (2008) The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Mol Cancer Ther 7(11):3566\u20133574","journal-title":"Mol Cancer Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06778-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T02:34:07Z","timestamp":1699842847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06778-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6778"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06778-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}